Cancer is a complex and dynamic foe. The Damon Runyon Board is committed to providing a framework for identifying, mentoring, and funding brilliant young scientists who have the talent and imagination to make paradigm-shifting strides in understanding and disrupting its mechanisms.”


Deborah J. Coleman*

Boston, Massachusetts

* Indicates member serves on the Scientific Committee

Vice Chair, Scientific Programs

William G. Kaelin, Jr., MD*
Sidney Farber Professor of Medicine
Dana-Farber Cancer Institute and
Harvard Medical School
Howard Hughes Medical Institute Investigator
Boston, Massachusetts


Vice Chair, Investments and Treasurer

David G. Marshall
Chairman and Chief Executive Officer
Amerimar Realty Company
Philadelphia, Pennsylvania



Vice Chair, Audit and Secretary

Sanford W. Morhouse, Esq.
Of Counsel
Schulte Roth & Zabel LLP
New York, New York



While I select my investments based on return on investment, I select my charities based on impact. Year after year, Damon Runyon selects the best new minds in cancer research and funds their bold ideas for preventing and curing cancer. Year after year, its scientists go on to make major breakthroughs. That’s real impact.”

Leon G. Cooperman

Vice Chair, Board Development

Michael L. Gordon*
Chief Executive Officer and
Chief Investment Officer
Angelo Gordon
New York, New York

Vice Chair

David M. Beirne
General Partner
X10 Capital
San Francisco, California

Vice Chair 

Leon G. Cooperman
Chairman and Chief Executive Officer
Omega Operating, LLC
New York, New York

Vice Chair 

Alan M. Leventhal
Chairman and Chief Executive Officer
Beacon Capital Partners, LLC
Boston, Massachusetts



Carlos L. Arteaga, MD*
Director of the Simmons Comprehensive Cancer Center
Associate Dean of Oncology Programs
University of Texas Southwestern Medical Center
Dallas, Texas



Steven J. Burakoff, MD*
Dean for Cancer Innovation
The Tisch Cancer Institute
Chief, Division of Pediatric Hematology and Oncology
Lillian and Henry M. Stratton Professor of
Cancer Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Robyn Coles
TRATE Properties LLC
Boston, Massachusetts



Gary E. Erlbaum
Greentree Properties
Ardmore, Pennsylvania


Thomas J. Fahey, Jr., MD*
Senior Vice President Emeritus
Memorial Sloan Kettering Cancer Center
New York, New York

Buck French
General Partner
X10 Capital
San Francisco, California

Elaine V. Fuchs, PhD*
Head, Laboratory of Mammalian Cell Biology and Development
Rebecca C. Lancefield Professor
The Rockefeller University
Howard Hughes Medical Institute Investigator
New York, New York

Levi A. Garraway,
MD, PhD*

Executive Vice President
Chief Medical Officer and Head of Product Development
Genentech, Inc.
South San Francisco, California

Richard B. Gaynor, MD*
President and Chief of Research and Development
BioNTech US
Cambridge, Massachusetts



Receiving a Damon Runyon Fellowship had a tremendous impact on my scientific career. I also have been fortunate to mentor new Damon Runyon scientists in my lab who have gone on to have exemplary independent careers. Damon Runyon builds generations of scientific leaders and mentors.”

Elaine V. Fuchs, PhD

(Damon Runyon Fellow ‘77-‘79)

Todd R. Golub, MD*
Director and Founding Core Institute Member
Broad Institute of MIT and Harvard
Charles A. Dana Investigator in Human Cancer Genetics
Dana-Farber Cancer Institute
Professor of Pediatrics
Harvard Medical School
Cambridge, Massachusetts

Scott Greenstein
President and Chief Content Officer
New York, New York





Steve Hayden
Vice Chairman and Chief Creative Officer (Retired)
Ogilvy & Mather Worldwide
New York, New York





Morana Jovan-Embiricos, PhD*
Managing Partner
F2 Capital Ventures LLP
London, United Kingdom

Steven A. Kandarian
Chairman, President and Chief Executive Officer (Retired)
MetLife, Inc
North Palm Beach, Florida

Noah Knauf
General Partner
Bond Capital
San Francisco, California

Gabrielle Layton, PhD
Palo Alto, California

David M. Livingston, MD*
Emil Frei Distinguished Professor of Genetics and Medicine
Harvard Medical School and
Dana-Farber Cancer Institute
Boston, Massachusetts

Richard W. Meier
The Bakewell Foundation
St. Louis, Missouri

John H. Myers
President (retired)
GE Asset Management
Fairfield, Connecticut

Richard J. O’Reilly, MD*
Claire L. Tow Chair, Pediatric Oncology Research
Memorial Sloan Kettering Cancer Center
New York, New York

Andrew S. Rachleff
President and Chief Executive Officer
Wealthfront, Inc.
Palo Alto, California

Meghan Raveis
Managing Director
William Raveis Charitable Fund
Shelton, Connecticut

Michael V. Seiden, MD, PhD*
The US Oncology Network
The Woodlands, Texas

Karen D. Seitz
Founder and Managing Director
Fusion Partners Global LLC
New York, New York

In Silicon Valley, we have witnessed brilliant young minds with bold ideas change the world. Damon Runyon makes this happen for cancer research. It identifies top emerging talent and encourages their high risk/high reward ideas. The payoff has been generations of game-changers.”

Andy and Debbie Rachleff

Nancy Simonian, MD*
Chief Executive Officer
Syros Pharmaceuticals, Inc.
Cambridge, Massachusetts

Cynthia Sulzberger
Wellington, Florida

Judy C. Swanson
Hillsborough, California

Nat Turner
Co-Founder and Chief Executive Officer
Flatiron Health
New York, New York

Peter Van Camp
Executive Chairman
Equinix, Inc.
Redwood City, California

James A. Wells, PhD*
Harry Wm. and Diana V. Hind
Distinguished Professor in Pharmaceutical Sciences
Professor, Molecular and Cellular Pharmacology
University of California, San Francisco
San Francisco, California